We Give Shareholders A Voice.

The market fluctuates, but we don’t. We give you straight answers from real attorneys who have spent decades helping shareholders protect their investments and recover their losses.

Settlements

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

I think you’ve done a superb job and I really appreciate the way this case was handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct. for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No. 600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290 (S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our “extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management, kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

Who We Are

1
1
1
1
1
1

We're here for you

Find an Attorney

Required Field

Coin Image

Don't hesitate

Find a Case

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

4

Days Left

VNET

VNET Group, Inc.

Deadline

February 26 2024

Class Period

4/8/22 - 2/15/23

Allegations

(1) GenTao, which is owned by VNET, was experiencing financial difficulties and was at risk of defaulting on the facility agreement that VNET's co-founder, Josh Sheng Chen had entered into with Bold Ally; (2) as a result, there was a substantial likelihood that Bold Ally would acquire Sheng Chen’s significant ownership stake in VNET; (3) to restore Sheng Chen’s voting interest in VNET, the Company would issue newly created shares to Sheng Chen, diluting investors’ interest; (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

4/8/22 - 2/15/23

Deadline

February 26 2024

Learn More

12

Days Left

ASRT

Assertio Holdings, Inc.

Deadline

March 5 2024

Class Period

3/29/23 - 11/8/23

Allegations

(i) the Company’s reliance on Indocin products to boost its net income was unsustainable given the risk of generic competition; (ii) Assertio's acquisition of Spectrum Pharmaceuticals, Inc. and Spectrum’s injection asset, Rolvedon, was less valuable than Assertio had represented to investors; (iii) accordingly, Assertio had overstated the positive impact the sale of Indocin products and the acquisition were likely to have on the Company’s profitability; and (iv) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

3/29/23 - 11/8/23

Deadline

March 5 2024

Learn More

18

Days Left

DADA

Dada Nexus Limited

Deadline

March 11 2024

Class Period

5/11/23 - 1/8/24

Allegations

(1) Dada revenues from online advertising, marketing services, and operations and support costs were materially overstated; (2) as a result, Dada would need to conduct an independent review to ascertain the financial impact and the scope of suspicious practices that led to overstated revenues and costs; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

5/11/23 - 1/8/24

Deadline

March 11 2024

Learn More

19

Days Left

BNTX

BioNTech SE

Deadline

March 12 2024

Class Period

3/30/22 - 10/13/23

Allegations

(i) BioNTech overstated demand for and/or the commercial prospects of Comirnaty, the COVID-19 vaccine developed by the Company in collaboration with Pfizer ; (ii) the Company and/or Pfizer had accumulated excess inventory of raw materials for Comirnaty, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants that were produced at risk; (iii) accordingly, BioNTech was at an increased risk of recording significant inventory write-offs and other charges related to Comirnaty; and (iv) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

3/30/22 - 10/13/23

Deadline

March 12 2024

Learn More

25

Days Left

MBLY

Mobileye Global Inc.

Deadline

March 18 2024

Class Period

1/16/23 - 1/3/24

Allegations

(1) to avoid the shortages experienced amid supply chain constraints in 2021 and 2022, the Company’s Tier 1 customers had purchased inventory in excess of demand during fiscal 2023; (2) as a result, the Company’s customers had excess inventory on hand, including approximately 6-7 million units of EyeQ SoCs; (3) due to the build-up of inventory, there was a significant risk that the Tier 1 customers would buy less product, thus adversely impacting the Company’s fiscal 2024 financial results; and (4) as a result of the foregoing, defendant’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

1/16/23 - 1/3/24

Deadline

March 18 2024

Learn More

26

Days Left

ALVR

AlloVir, Inc.

Deadline

March 19 2024

Class Period

3/22/22 - 12/21/23

Allegations

(i) the posoleucel Phase 3 Studies were unlikely to meet their primary endpoints; (ii) as a result, it was likely that the Company would ultimately discontinue the posoleucel Phase 3 studies; (iii) accordingly, AlloVir overstated the efficacy and clinical and/or commercial prospects of posoleucel; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

3/22/22 - 12/21/23

Deadline

March 19 2024

Learn More

26

Days Left

BIVI

BioVie Inc.

Deadline

March 19 2024

Class Period

8/5/21 - 11/29/23

Allegations

(1) BioVie was not conducting proper oversight of its Phase 3 clinical trial; (2) the COVID-19 pandemic significantly and negatively impacted the Company's ability to adequately conduct proper oversight of the Phase 3 clinical trial; (3) due to lack of proper oversight and reliance on contract research organizations, the data from defendants' Phase 3 clinical trial faced a greater risk of being unreliable and that the majority of patients would have to be excluded from the clinical trial; (4) as a result of the significant exclusions from the trial results, the Phase 3 clinical trial would fail to meet its primary endpoints; and (5) statements about BioVie's business, operations, prospects, and compliance with current good clinical practices were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Class Period

8/5/21 - 11/29/23

Deadline

March 19 2024

Learn More

32

Days Left

ADM

Archer-Daniels-Midland Company

Deadline

March 25 2024

Class Period

4/30/20 - 1/22/24

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose material facts about the performance and prospects of ADM’s Nutrition segment and its accounting practices. Specifically, defendants made positive statements about the Nutrition segment as a future profit-driver for the Company, with the ability to capitalize on healthier eating trends and rising consumer demand for natural ingredients and flavoring. Defendants also created the impression that the Nutrition segment’s growth would provide more diversification and earnings stability for ADM.

Class Period

4/30/20 - 1/22/24

Deadline

March 25 2024

Learn More

32

Days Left

EVVTY

Evolution AB (publ)

Deadline

March 25 2024

Class Period

2/14/19 - 10/25/23

Allegations

(1) in “allowing play” from certain jurisdictions, multiple customers of Evolution AB’s were, or were deemed by regulators to be, unlicensed and/or in breach of the laws of those jurisdictions; and (2) defendants’ statements were false, as they misrepresented the extent of Evolution AB’s involvement with regulatorily noncompliant customers. When the true details entered the market, the lawsuit claims that investors suffered damages.

Class Period

2/14/19 - 10/25/23

Deadline

March 25 2024

Learn More

32

Days Left

RILY

B. Riley Financial, Inc.

Deadline

March 25 2024

Class Period

5/10/23 - 11/9/23

Allegations

(1) Brian Kahn, a client of the Company, had been credibly implicated in a conspiracy to defraud investors of millions of dollars; (2) in spite of this involvement, B. Riley continued to finance the transaction enabling Kahn and others to take Franchise Group, Inc. private through complex arrangements; (3) the foregoing was reasonably likely to draw regulatory scrutiny to B. Riley; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/10/23 - 11/9/23

Deadline

March 25 2024

Learn More

32

Days Left

CART

Maplebear Inc. d/b/a Instacart

Deadline

March 25 2024

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities other than defendants that purchased or otherwise acquired: (a) Instacart common stock pursuant and/or traceable to offering documents issued in connection with the Company’s initial public offering conducted on or about September 19, 2023; and/or (b) Instacart securities between September 19, 2023 and October 1, 2023, both dates inclusive.

Allegations

(i) Instacart had overstated the extent to which online grocery shopping and delivery habits among consumers were accelerating; (ii) Instacart had downplayed the extent of the competition that it faced in the online grocery shopping and delivery market; (iii) accordingly, defendants overstated the Company’s post-initial public offering growth, business, and financial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities other than defendants that purchased or otherwise acquired: (a) Instacart common stock pursuant and/or traceable to offering documents issued in connection with the Company’s initial public offering conducted on or about September 19, 2023; and/or (b) Instacart securities between September 19, 2023 and October 1, 2023, both dates inclusive.

Deadline

March 25 2024

Learn More

32

Days Left

EAF

GrafTech International Ltd.

Deadline

March 25 2024

Class Period

2/8/19 - 8/3/23

Allegations

(a) GrafTech’s manufacturing operations in Monterrey, Mexico had for decades chronically contaminated neighboring communities with harmful carcinogenic gasses and particulate matter; (b) GrafTech had signed agreements with local authorities committing itself to improving the environmental performance of its Monterrey facility, but repeatedly failed to honor these commitments; (c) GrafTech had been repeatedly warned over an approximately 30-year period regarding its wanton disregard for the environment and health and well-being of people near its operations in Monterrey, Mexico; (d) GrafTech’s operations in Monterrey, Mexico were not in compliance with applicable environmental laws and regulations; (e) the Company had failed to adequately remediate the environmental problems caused by the Monterrey facility following the 2019 administrative proceeding conducted by the Department of Sustainable Development of the State of Nuevo León; (f) the government of Apodaca had sought intervention from the State of Nuevo León authorities to curtail and prevent the adverse environmental impacts and noncompliance with environmental laws and regulations caused by the Monterrey facility; (g) GrafTech’s purported cost leadership was achieved in substantial part by failing to implement appropriate and effective environmental safeguards at its manufacturing facility in Monterrey, Mexico; (h) GrafTech’s capital expenditures and/or related operational projects were woefully insufficient to adequately address the harm that the Company’s operations in Monterrey, Mexico had inflicted on the environment and people within the neighboring communities; (i) as a result of (a)-(h), GrafTech was acutely exposed to undisclosed material risks that the Company’s manufacturing operations in Monterrey, Mexico would be severely disrupted by government action or enforcement; and (j) as a result of (a)-(i), GrafTech was acutely exposed to undisclosed material risks that its supplies of pin stock and graphite electrodes would be withdrawn and/or materially diminished, thereby materially harming the Company’s business, operations, reputation, and financial results.

Class Period

2/8/19 - 8/3/23

Deadline

March 25 2024

Learn More

32

Days Left

BTI

British American Tobacco p.l.c.

Deadline

March 25 2024

Class Period

2/9/23 - 12/6/23

Allegations

(1) British American Tobacco materially understated the risks and potential likelihood of an impairment to its Premium American Cigarette Brands as a result of various longstanding headwinds and; (2) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

2/9/23 - 12/6/23

Deadline

March 25 2024

Learn More

40

Days Left

SAVA

Cassava Sciences, Inc.

Deadline

April 2 2024

Class Period

8/18/22 - 10/12/23

Allegations

(i) the Company failed to maintain adequate and effective data management controls and procedures related to its drug research programs; (ii) as a result, the data published in support of the Company’s lead therapeutic drug candidate, PTI-125 (or “simufilam”), were susceptible to manipulation to overstate the drug’s effectiveness; (iii) accordingly, Cassava had misrepresented the efficacy of its research programs and the clinical and/or commercial prospects of simufilam; (iv) all of the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

8/18/22 - 10/12/23

Deadline

April 2 2024

Learn More

46

Days Left

IRTC

iRhythm Technologies, Inc.

Deadline

April 8 2024

Class Period

1/11/22 - 5/30/23

Allegations

According to the lawsuit, defendants falsely represented to investors that one of iRhythm’s main products, the Zio AT monitor, was a real-time heart monitor intended for high-risk patients. Specifically, defendants repeatedly touted the potential growth for the Zio AT as an innovative product that had only just begun to penetrate the market for real-time monitoring, which investors looked upon favorably given the premium selling price associated with devices approved for high-risk patients. As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the class period.

Class Period

1/11/22 - 5/30/23

Deadline

April 8 2024

Learn More

46

Days Left

NYCB

New York Community Bancorp, Inc.

Deadline

April 8 2024

Class Period

3/1/23 - 1/30/24

Allegations

(1) the Company was experiencing higher net charge-offs and deterioration in its office portfolio; (2) as a result, NYCB was reasonably likely to incur higher loan losses; (3) as a result of the foregoing and NYCB’s status as Category IV bank, the Company was reasonably likely to increase its allowance for credit losses; (4) the Company’s financial results would be adversely affected; (5) to preserve capital, the Company would reduce quarterly common dividend to $0.05 per common share; and (6) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

3/1/23 - 1/30/24

Deadline

April 8 2024

Learn More

46

Days Left

HUT

Hut 8 Corp.

Deadline

April 8 2024

Class Period

11/9/23 - 1/18/24

Allegations

(1) one of the largest shareholders in U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”), one of the companies that merged to create Hub 8, is an undisclosed related party; (2) one of USBTC’s core assets has historically failed to provide energy and high-speed internet; (3) the profitability of certain USBTC assets were overstated; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/9/23 - 1/18/24

Deadline

April 8 2024

Learn More

47

Days Left

XPOF

Xponential Fitness, Inc.

Deadline

April 9 2024

Class Period

7/26/21 - 12/7/23

Allegations

(a) Xponential had permanently closed at least 30 stores; (b) Xponential’s reported SSS and AUV metrics had been misstated by excluding underperforming stores; (c) 8 out of 10 Xponential brands were losing money monthly; (d) over 50% of Xponential studios did not make a positive financial return; (e) over 60% of Xponential’s revenue was one-time and nonrecurring; (f) more than 100 of the Company’s franchises were for sale at a price that is at least 75% less than their initial cost; (g) Xponential had misled many of its franchisees into opening franchises by misrepresenting the financial profile and profitability of its studios, as well as the expected rate of return for new studio openings; (h) many Xponential franchisees were substantially in debt, suffering high attrition rates and running non-viable studios that had no realistic path to profitability; and (i) based on the foregoing, defendants lacked a reasonable factual basis for their positive statements about Xponential’s then-current business operations and future financial prospects.

Class Period

7/26/21 - 12/7/23

Deadline

April 9 2024

Learn More

47

Days Left

AMLX

Amylyx Pharmaceuticals, Inc.

Deadline

April 9 2024

Class Period

11/11/22 - 11/8/23

Allegations

(i) defendants had overstated RELYVRIO’s (a dual UPRBax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol, for the treatment of ALS in adults in the U.S.) commercial prospects; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, defendants had also overstated RELYVRIO’s prescription rate; (v) defendants attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO’s prescription data; and (vi) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Class Period

11/11/22 - 11/8/23

Deadline

April 9 2024

Learn More

53

Days Left

AMPL

Amplitude, Inc.

Deadline

April 15 2024

Class Period

9/21/21 - 2/16/22

Allegations

(a) Amplitude’s land-and-expand strategy was years away from significantly accelerating revenues among its newer client cohorts; (b) the rapid acceleration in the Company’s 2Q21 results resulted from the ephemeral effects of the COVID-19 pandemic which had not continued by the start of the class period, as Amplitude clients were expanding at a slower pace; and (c) as a result of (a)-(b) above, Amplitude’s business, operations, financial results, and prospects were materially worse than represented to investors during the class period.

Class Period

9/21/21 - 2/16/22

Deadline

April 15 2024

Learn More

53

Days Left

INMD

InMode Ltd.

Deadline

April 15 2024

Class Period

6/4/21 - 10/12/23

Allegations

(1) the price at which InMode sells its devices, which reflects the demand for those products; and (2) InMode’s compliance with U.S. Food and Drug Administration (“FDA”) regulations, including the FDA’s prohibition on off-label marketing of devices and the FDA’s requirements for the reporting of injuries. Specifically, defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount. InMode also assured investors that it had “obtained [FDA] clearance for the current treatments for which we offer our products” and that “no third-party claims have been brought against us to date.” As a result of these misrepresentations, the price of InMode common stock traded at artificially inflated prices throughout the class period.

Class Period

6/4/21 - 10/12/23

Deadline

April 15 2024

Learn More

54

Days Left

NOVA

Sunnova Energy International Inc.

Deadline

April 16 2024

Class Period

2/25/20 - 12/7/23

Allegations

(i) Sunnova routinely engaged in predatory business practices against disadvantaged homeowners and communities, the same groups that Project Hestia (the “LPO Loan”) was purportedly intended to benefit; (ii) the foregoing conduct subjected the company to a heightened risk of regulatory and/or governmental scrutiny, as well as significant reputational and/or financial harm; and (iii) as a result, the company’s public statements were materially false and misleading at all relevant times.

Class Period

2/25/20 - 12/7/23

Deadline

April 16 2024

Learn More

News

Stay informed with the latest in settlement notices, case updates, publications, analyst reports, and more.
View All News

Learn More

Levi & Korsinsky to Serve as Lead Counsel in Generac Class Action Lawsuit
Christopher Walling v. Generac Holdings, Inc., et al., 3:23-cv-0080 is a lawsuit currently pending in the United States District Court for the Western District of Wisconsin. The action was filed on behalf of investors in Generac Holdings, Inc. (NYSE: GNRC) who allegedly suffered losses due to securities fraud by the company. On February 7, 2024,...Read more

February 13, 2024

Learn More

Levi & Korsinsky Announces $9.5 Million Alloy Steel Merger Settlement
In the class action captioned Karsan Value Funds v. Kostecki Brokerage Pty Ltd., C.A. No. 2021-0899-LWW (Del. Ch),  plaintiffs Karsan Value Funds and Robert Gruters, on behalf of themselves and a class comprised of all unaffiliated stockholders of Alloy Steel, Inc. as of September 17, 2021, have reached a proposed settlement with defendants Kostecki Brokerage...Read more

February 2, 2024

Learn More

Court Preliminary Approves Settlement Against Corcept Therapeutics Incorporated
Update Ferraro Family Foundation, Inc. and James L. Ferraro v. Corcept Therapeutics, Inc., et. al., Case No. 3:19-cv-0372-JD (N.D. Cal.): A settlement has been reached and was preliminarily approved on January 4, 2024. The settlement provides for the payment of $14 million to eligible class members.  Lead plaintiff Ferraro Family Foundation, Inc. and James L....Read more

January 26, 2024

Our World-Class Team

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal courts across the country. We have the specialized securities skills to achieve outstanding results, and our impressive variety of backgrounds means that we can go up against large companies of any kind and win. Our powerhouse attorneys have backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory analysis, international business, and prosecution, to name just a few. . .

View Attorneys